Texas judge rules Allergan ’s Restasis patents invalid
U.S. judge William Bryson ruled that patents covering Allergan‘s (NYSE:AGN) Restasis medicine are invalid on the grounds of obviousness, driving the company’s shares down more than -6% in afternoon trading today. The decision, made in a Texas federal court, is part of an ongoing case between Allergan and generic drugmakers like Mylan (NSDQ:MYL) and Teva Pharmaceuticals (NYSE:TEVA). Get the full story at our sister site, Drug Delivery Business News. The post Texas judge rules Allergan’s Restasis patents invalid appeared first on MassDevice.
A consistent increase in the intensity and length of allergy season in regions of the United States signals a difficult season in 2020, at the same time as the COVID-19 pandemic affects communities.Medscape Medical News
‘Grandfather of allergy’ survived three years in Japanese POW camp before pioneering medical careerDr William Frankland, a pioneering British immunologist who transformed the world ’s understanding of allergies, has died aged 108.Frankland improved the lives of millions of hay fever sufferers by developing the idea of apollen count. Until his death the oldest survivor of the Japanese prisoner of war camps, he published a scientific paper in September 2017 aged 105.Continue reading...
Authors: Siah KTH, Santosa A, Cheung CKY, Soh AYS, Bigliardi PL Abstract Background/Aims: The relationship between animal exposure and irritable bowel syndrome (IBS) is debated. Epidemiological studies have shown that atopy is more prevalent in IBS patients and vice versa. We set out to examine the association between animal danders sensitization and IBS-like symptoms in atopic patients. Methods: We recruited 69 consecutive atopic patients from the allergy clinic of a tertiary hospital. Subjects completed validated bowel questionnaires, underwent skin prick test, blood was collected for serum total immunoglobul...
UCLA Health is one of 75 sites around the globe participating in a clinical trial sponsored by the National Institutes of Health to test the effectiveness of a candidate antiviral drug against COVID-19.The drug, called remdesivir, was originally developed as a treatment for Ebola. Although it was found to be safe, it was not effective in treating patients with the disease. In laboratory tests, however, it appears to work against the SARS-CoV-2 virus that causes COVID-19, which has raised hope that it may be effective against the coronavirus that has swept the globe, sickening and killing thousands.The clini...
Publication date: Available online 3 April 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Katarzyna Mycroft, Rafal Krenke, Katarzyna Gorska
Publication date: Available online 3 April 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Joel P. Brooks, Cristine Radojicic, Marc A. Riedl, Scott D. Newcomer, Aleena Banerji, F. Ida Hsu
Publication date: Available online 2 April 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Yuliya Afinogenova, Tamar Rubin, Sagar Patel, Rachel Powell, Janina Gilo, Morgan Denno, Gary Soffer, Jason Lee, Louis Mendelson, Jeffrey Factor
Those on steroids because of known adrenal disease, and for more common ailments, may need additional'stress'doses of IV corticosteroids in the case of severe infection with COVID-19, endocrinologists urge.Medscape Medical News
Most allergy and immunology care could be postponed or handled virtually during the COVID-19 pandemic, according to consensus-based recommendations.Reuters Health Information
April 3, 2020—(BRONX, NY)—Montefiore Health System andAlbert Einstein College of Medicine has joined a clinical trial to evaluate the experimental drug remdesivir to treat people who are hospitalized with severe COVID-19 infection. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is sponsoring the trial. This treatment has the potential to help people who have serious lung complications as a result of COVID-19. Recruitment for the trial began in March and is still underway.